“Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP)

Gravas S et al (2015) Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO). https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2015-v2.pdf

Gilling PJ et al (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 109(3):408–411

Lourenco T et al (2008) Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ 337:a449

Tan A et al (2007) Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 94(10):1201–1208

Yin L et al (2013) Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol 27(5):604–611

Elmansy H et al (2012) Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol 188(1):216–221

Elmansy HM, Kotb A, Elhilali MM (2011) Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol 186(5):1972–1976

Krambeck AE, Handa SE, Lingeman JE (2013) Experience with more than 1000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 189(1 Suppl):S141–S145

Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 53(1):160–166

Tooher R et al (2004) A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. J Urol 171(5):1773–1781

van Rij S, Gilling PJ (2012) In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new ‘gold standard’. Curr Urol Rep 13(6):427–432

Gratzke C et al (2015) EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 67(6):1099–1109

Mottet N et al (2015) Guidelines on Prostate Cancer; European Association of Urology 2015. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf

Nunez R et al (2011) Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol 18(7):543–547

Naspro R et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171(3):1203–1206

Kim M et al (2014) Prostate cancer detected after Holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography. Int Urol Nephrol 46(11):2079–2085

Bhojani N et al (2015) Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol 29(1):41–46

Rivera ME et al (2014) Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer: an outcomes analysis. J Endourol 28(6):699–703

Sakamoto H et al (2014) Preoperative parameters to predict incidental (T1a and T1b) prostate cancer. Can Urol Assoc J 8(11–12):E815–E820

Otto B et al (2014) Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol 2014:627290

Voigt S et al (2011) Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate 71(12):1325–1331

Melchior S et al (2009) Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 103(11):1478–1481

Argyropoulos A et al (2005) Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol 39(4):289–293

Jones JS, Follis HW, Johnson JR (2009) Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis 12(1):57–60

Elkoushy MA, Elshal AM, Elhilali MM (2015) Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology 86(3):552–557

Benson MC et al (1993) An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol 11(4):206–213

Carter HB et al (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21):1521–1527

Ciatto S et al (2001) Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting. Int J Biol Markers 16(3):179–182

Helfand BT et al (2009) Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology 74(1):177–183

Kuriyama M et al (1999) Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 29(12):617–622

Stephan C et al (2002) Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48(8):1279–1287

Michalak J, Tzou D, Funk J (2015) HoLEP: the gold standard for the surgical management of BPH in the 21(st) Century. Am J Clin Exp Urol 3(1):36–42

Stephan C et al (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 104(5):993–1003

Delongchamps NB, Portalez D, Bruguière E, Rouvière O, Malavaud B, Mozer P, Fiard G, Cornud F, MURIELLE Study Group (2016) Are MRI-TRUS-guided targeted biopsies non-inferior to TRUS-guided systematic biopsies for the detection of prostate cancer in patients with a single suspicious focus on multiparametric prostate MRI? Results of a multicentric controlled trial. J Urol 196(4):1069–1075. doi: 10.1016/j.juro.2016.04.003